BAX 📈 Baxter International - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0718131099

BAX: Infusion Systems, Surgical Equipment, Diagnostic Technologies, Dialysis Therapies

Baxter International Inc. is a leading global healthcare company that develops and provides a diverse range of medical products and services to patients, hospitals, and healthcare providers worldwide. Through its four main business segments - Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care - the company offers a comprehensive portfolio of solutions that cater to various healthcare needs.

The company's product offerings include sterile IV solutions, infusion systems, and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices. Additionally, Baxter provides administrative sets, adhesion prevention products, inhaled anesthesia, and drug compounding services, as well as chronic and acute dialysis therapies and services, including peritoneal dialysis, hemodialysis, continuous renal replacement therapies, and other organ support therapies.

Baxter's products are designed to improve patient outcomes and are used in various healthcare settings, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients' homes under physician supervision. The company's global reach extends to approximately 100 countries, where it sells its products through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers.

In addition to its product offerings, Baxter has strategic partnerships and collaborations aimed at advancing patient care. For instance, the company has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products, and a collaborative research agreement with Miromatrix Medical Inc. to advance care for patients with acute liver failure. With a rich history dating back to 1931, Baxter International Inc. is headquartered in Deerfield, Illinois, and continues to innovate and expand its healthcare solutions globally.

Additional Sources for BAX Stock

BAX Stock Overview

Market Cap in USD 16,318m
Sector Healthcare
Industry Medical Instruments & Supplies
GiC Industry Health Care Equipment & Supplies
TER 0.00%
IPO / Inception 1981-10-27

BAX Stock Ratings

Growth 5y -80.4%
Fundamental 20.7%
Dividend 56.1%
Rel. Performance Sector -1.91
Analysts 3.27/5
Fair Price Momentum 27.98 USD
Fair Price DCF 1.37 USD

BAX Dividends

Dividend Yield 12m 2.63%
Yield on Cost 5y 1.16%
Annual Growth 5y 6.42%
Payout Consistency 94.04%

BAX Growth Ratios

Growth Correlation 3m -91.3%
Growth Correlation 12m -44.8%
Growth Correlation 5y -89%
CAGR 5y -15.11%
CAGR/Mean DD 5y -0.49
Sharpe Ratio 12m -0.22
Alpha -27.13
Beta 0.60
Volatility 31.53%
Current Volume 3717.6k
Average Volume 20d 4850.7k
What is the price of BAX stocks?
As of December 04, 2024, the stock is trading at USD 33.13 with a total of 3,717,568 shares traded.
Over the past week, the price has changed by +1.31%, over one month by -6.98%, over three months by -12.02% and over the past year by -7.60%.
Is Baxter International a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Baxter International is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 20.73 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BAX as of December 2024 is 27.98. This means that BAX is currently overvalued and has a potential downside of -15.54%.
Is BAX a buy, sell or hold?
Baxter International has received a consensus analysts rating of 3.27. Therefor, it is recommend to hold BAX.
  • Strong Buy: 3
  • Buy: 0
  • Hold: 11
  • Sell: 0
  • Strong Sell: 1
What are the forecast for BAX stock price target?
According to ValueRays Forecast Model, BAX Baxter International will be worth about 30.2 in December 2025. The stock is currently trading at 33.13. This means that the stock has a potential downside of -8.78%.
Issuer Forecast Upside
Wallstreet Target Price 40.5 22.3%
Analysts Target Price 47.1 42.1%
ValueRay Target Price 30.2 -8.8%